Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Announces Common Stock Offering

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has announced its common stock offering of about 5,200,000 shares as well as the pricing details with the stock price coming in at $5.50 per share. Conatus’ common stock offering is expected to bring in about $28.6 million before underwriting the costs, discounts and commissions. The company plans to pump roughly […]

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Releases Updates On Clinical Development Programs.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is advancing its lead compound, named as emricasan, for the treating patients with chronic liver disease. The firm recently initiated ENCORE-PH, which is a randomized, placebo-controlled, double-blind Phase IIb clinical study commenced in November 2016 assessing the impact of emricasan in minimizing hepatic venous pressure gradient in subjects with early decompensated […]

Before You Trade: Double Eagle Petroleum Co (NASDAQ:DBLE), Clovis Oncology Inc (NASDAQ:CLVS), Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

Boston, MA 03/27/2014 (wallstreetpr) – The anticipated change of guard and name at Double Eagle Petroleum Co (NASDAQ:DBLE) seem to be taken positively among investors. Moreover, promises by the company to expand its operations, attract more industry experts and boost income are all coming as good news to the shareholders. The company, in a statement, […]